For research use only. Not for therapeutic Use.
Tregalizumab is a humanized anti-human CD4 monoclonal antibody (IgG1 type) that selectively activates the suppressive properties of regulatory T cells (Tregs) in vitro. Tregalizumab can be used in the research of autoimmune diseases (resulting from insufficient Treg activity) and allergies[1][2][3].
Tregalizumab is able to activate the suppressive capacity of regulatory T cells[1].
Tregalizumab reduces proliferation and cytokine secretion when isolated PBMCs are stimulated with tetanus toxoid in a dose-dependent manner[1].
Tregalizumab (0-30 µg/mL; 18 h) treatment of PBMC induces CD4 down-modulation of T cells[2].
Tregalizumab primarily induces CD4 down-modulation at inflammatory sites[2].
| Catalog Number | I042251 |
| CAS Number | 1207446-68-1 |
| Purity | ≥95% |
| Reference | [1]. König M, et al. Tregalizumab – A Monoclonal Antibody to Target Regulatory T Cells. Front Immunol. 2016 Jan 25;7:11. [2]. Vogel S, et al. Antibody induced CD4 down-modulation of T cells is site-specifically mediated by CD64(+) cells. Sci Rep. 2015 Dec 16;5:18308. [3]. Helling B, et al. A specific CD4 epitope bound by tregalizumab mediates activation of regulatory T cells by a unique signaling pathway. Immunol Cell Biol. 2015 Apr;93(4):396-405. |
